Evidence map›Paper›PMID 40770488›Full record

ArticleCommunications biology2025

Interpretable and integrative analysis of single-cell multiomics with scMKL.

Samuel D Kupp, Ian A VanGordon, Mehmet Gönen, Sadık Esener, Sebnem Ece Eksi, Çiğdem Ak

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Samuel D KuppCancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, OHSU, Portland, OR, USA.ORCID http://orcid.org/0009-0004-4888-9213
Ian A VanGordonCancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, OHSU, Portland, OR, USA.
Mehmet GönenDepartment of Industrial Engineering, College of Engineering, Koç University, İstanbul, Türkiye.ORCID http://orcid.org/0000-0002-2483-075X
Sadık EsenerCancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, OHSU, Portland, OR, USA.ORCID http://orcid.org/0000-0002-6873-0478
Sebnem Ece EksiCancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, OHSU, Portland, OR, USA.ORCID http://orcid.org/0000-0003-1012-5571
Çiğdem AkCancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, OHSU, Portland, OR, USA. ak@ohsu.edu.ORCID http://orcid.org/0000-0003-2563-4539

Funding

High Performance Computing and Machine Learning Infrastructure for Oregon Life SciencesS10OD034224 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLROTT, KYLE · 2023 to 2023
$2.0M
NIH HHS S10 OD034224
6 · The paper itself

Abstract

The rapid advancement of single-cell technologies has led to the development of various analysis methods, each with trade-offs between predictive power and interpretability particularly for multimodal data integration. Complex machine learning models achieve high accuracy, but they often lack transparency, while simpler models are more interpretable but less effective for prediction. In this manuscript, we introduce an innovative method for single-cell analysis using Multiple Kernel Learning (scMKL), that merges the predictive capabilities of complex models with the interpretability of linear approaches, aimed at providing actionable insights from single-cell multiomics data. scMKL excels at classifying healthy and cancerous cell populations across multiple cancer types, utilizing data from single-cell RNA sequencing, ATAC sequencing, and 10x Multiome. It outperforms existing methods while delivering interpretable results that identify key transcriptomic and epigenetic features, as well as multimodal pathways- that existing methods have failed to achieve, in breast, lymphatic, prostate, and lung cancers. Leveraging insights from one dataset to inform analysis in a new dataset, scMKL uncovers biological pathways that distinguish treatment responses in breast cancer, low-grade from high-grade prostate tumors, and subtypes in lung cancer, thereby enhancing our understanding of cancer biology and tumor progression.

Indexed as

Machine LearningNeoplasmsSingle-Cell AnalysisFemaleHumansMaleMultiomicsTranscriptome

Identifiers

PMID40770488
PMCPMC12328712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.